2022
Factors associated with progression and mortality among patients undergoing stereotactic radiosurgery for intracranial metastasis: results from a national real-world registry.
Alvi MA, Asher AL, Michalopoulos GD, Grills IS, Warnick RE, McInerney J, Chiang VL, Attia A, Timmerman R, Chang E, Kavanagh BD, Andrews DW, Walter K, Bydon M, Sheehan JP. Factors associated with progression and mortality among patients undergoing stereotactic radiosurgery for intracranial metastasis: results from a national real-world registry. Journal Of Neurosurgery 2022, 137: 985-998. PMID: 35171833, DOI: 10.3171/2021.10.jns211410.Peer-Reviewed Original ResearchMultivariable Cox proportional hazards analysisCox proportional hazards analysisAdministration of immunotherapyProportional hazards analysisStereotactic radiosurgeryIntracranial metastatic lesionsMetastatic lesionsOverall progressionLesion responseInitial stereotactic radiosurgeryMultifraction stereotactic radiosurgeryProgressive intracranial diseaseNeuro-Oncology criteriaOutcomes of patientsReal-world registryResponse Evaluation CriteriaGood local controlIntracranial metastatic diseaseKaplan-Meier analysisCommon primary tumorHazard of progressionLarger lesion sizeSingle-fraction treatmentLesion regressionMedian survival
2020
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation
Kim AH, Tatter S, Rao G, Prabhu S, Chen C, Fecci P, Chiang V, Smith K, Williams BJ, Mohammadi AM, Judy K, Sloan A, Tovar-Spinoza Z, Baumgartner J, Hadjipanayis C, Leuthardt EC. Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN): 12-Month Outcomes and Quality of Life After Brain Tumor Ablation. Neurosurgery 2020, 87: e338-e346. PMID: 32315434, PMCID: PMC7534487, DOI: 10.1093/neuros/nyaa071.Peer-Reviewed Original ResearchConceptsKarnofsky performance scorePrimary tumorBaseline Karnofsky performance scoreCancer Therapy-BrainPostprocedure hospital stayReal-world registryPatient-reported QOLNeurological tissuesHigh-grade gliomasQuality of lifeReal-world outcomesBaseline comorbiditiesHospital stayAdverse eventsMost patientsOverall survivalMedian ageBrain tumor ablationRadiation necrosisPatient populationMetastatic cancerFunctional assessmentSurvival rateBaseline levelsQoL